Brief: Inhibikase Therapeutics Issues Letter To Shareholders And Provides Update On Development Programs
18/04/2024 21:39
April 18 (Reuters) - Inhibikase Therapeutics Inc
IKT.O :
* INHIBIKASE THERAPEUTICS ISSUES LETTER TO SHAREHOLDERS AND
PROVIDES UPDATE ON DEVELOPMENT PROGRAMS
* INHIBIKASE THERAPEUTICS - UPON COMPLETION OF
DOUBLE-BLINDED
PHASE OF 201 TRIAL, WE EXPECT TO REQUEST AN END OF PHASE 2
MEETING WITH FDA BY END OF 2024
Source text for Eikon: ID:nGNX3Qwlqb
Further company coverage: IKT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inhibikase Therapeutics
See all newsBrief: Inhibikase Therapeutics Prices Public Offering Of 46 Million Shares At $1.45 Per Share
Brief: Inhibikase Therapeutics Announces Proposed Public Offering Of Common Stock And Pre-Funded Warrants
Brief: Inhibikase Therapeutics Advancing IKT-001 To Global Phase 3 Study In Pulmonary Arterial Hypertension
Cardiopulmonary drugmaker Inhibikase Therapeutics' Q3 net loss widens
Inhibikase Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary